ADDISON, Texas, June 9, 2015 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) announced today interim results of a pharmacoeconomic evaluation being conducted in Europe.
The pharmacoeconomic data has two components. The first component is the costs associated with using Altrazeal® compared to both a conventional dry wound healing dressings and advanced moist wound dressings for an identical duration of treatment. The second component compares the cost of using Altrazeal® to conventional dry wound healing dressings and advanced moist wound dressings for the duration of treatment through wound closure.
Currently, the CE Mark in Europe allows for Altrazeal® to remain in place for up to 14 days. Clinical practice in this patient population resulted in Altrazeal® being changed on average every 9 days. Despite the unit cost of Altrazeal® being higher than competitive dressings, the reduction in dressing changes and the associated personnel costs makes Altrazeal® markedly economically preferable to conventional gauze dressings and advanced moist wound dressings including hydrocolloids, alginates, and foam dressings.
The interim data comparing Altrazeal® with conventional dry wound healing and advanced moist wound dressings on similar wounds for the duration of treatment through wound closure includes 43 patients treated with Altrazeal® and is as follows:
Therapeutic Approach | Dressing Changes Per week | Average Duration of Treatment to Wound Closure | Total Cost | ||
Per Dressing Change | |||||
Personnel Cost | Material Cost | ||||
Conventional Dry Wound Healing | 5.43 | 5.62 | 7 | 301 | 3,327 |
Advanced Moist Wound Healing | 5.43 | 9.67 | 3 | 98 | 634 |
Altrazeal® | 8.15 | 22.50 | Every 9th Day | 50 |
170 |
In the patient population evaluated, compared to patients in available data bases using conventional treatments, Altrazeal® demonstrated acceleration in wound healing. When combined with the lower treatment cost associated with using Altrazeal®, this generates a significant reduction in the cost to complete wound closure.
The cost comparison using Altrazeal® under the assumption of an identical 50 day period compared with alternative approaches is as follows:
Therapeutic Approach | Per Dressing Change | Dressing Changes Per Week | Total Cost | |
Personnel Cost | Material Cost | |||
Conventional Dry Wound Healing | 5.43 | 5.62 | 7 | 553 |
Advanced Moist Wound Healing | 5.43 | 9.67 | 3 | 324 |
Altrazeal® | 8.15 | 22.50 | Every 9th Day | 170 |
Commenting on the pharmacoeconomic data, Helmut Kerschbaumer, Managing Director of Altrazeal Trading GmbH, stated “This analysis confirms the extensive feedback that we have received regarding the clinical and economic benefits of Altrazeal®. As physicians gain greater clinical experience with Altrazeal® they could become more comfortable leaving the dressing in place for longer periods which will add further to the economic benefits. These data have been instrumental in justifying the pricing of Altrazeal® as it clearly demonstrates the advantages compared to competitive dressings. We are very excited with the preliminary data this evaluation has generated so far.”
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.
ULURU Inc. (OTCQB: ULUR) trades on the OTCQB Venture stage marketplace for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the economic and clinical benefits of Altrazeal®, the reduction in dressing changes, the acceleration of wound healing, and the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, and other reports filed by us with the Securities and Exchange Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uluru-inc-announces-interim-pharmacoeconomic-data-300096032.html
SOURCE ULURU Inc.
Help employers find you! Check out all the jobs and post your resume.
